Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
about
Insulin-like Growth Factor 1 Signaling Axis Meets p53 Genome Protection PathwaysUnderstanding the Key to Targeting the IGF Axis in Cancer: A Biomarker AssessmentTargeting insulin and insulin-like growth factor signaling in breast cancerCIViC databaseIGF-IR Targeted Therapy: Past, Present and FutureDurable Response of Spinal Chordoma to Combined Inhibition of IGF-1R and EGFRActivation of the Akt-mTOR pathway and receptor tyrosine kinase in patients with solitary fibrous tumors.The IGF Hormonal Network in Endometrial Cancer: Functions, Regulation, and Targeting ApproachesOncopig Soft-Tissue Sarcomas Recapitulate Key Transcriptional Features of Human SarcomasComparative evaluation of strategies for quantifying signaling pathway proteins in Ewing sarcoma.Insulin-like growth factor 1 receptor and response to anti-IGF1R antibody therapy in osteosarcoma.Can we unlock the potential of IGF-1R inhibition in cancer therapy?Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulationPrognostic and predictive role of CXCR4, IGF-1R and Ezrin expression in localized synovial sarcoma: is chemotaxis important to tumor response?Upregulation of IGF-1R expression during neoadjuvant therapy predicts poor outcome in breast cancer patients.Prognostic value of IGF-1R expression in bone and soft tissue sarcomas: a meta-analysis.Biomarkers in Ewing Sarcoma: The Promise and Challenge of Personalized Medicine. A Report from the Children's Oncology Group.Novel strategies for the treatment of chondrosarcomas: targeting integrins.Nuclearly translocated insulin-like growth factor 1 receptor phosphorylates histone H3 at tyrosine 41 and induces SNAI2 expression via Brg1 chromatin remodeling protein.Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.Analysis of serum insulin growth factor-1 concentrations in localized osteosarcoma: a children's oncology group studyTargeted imaging of Ewing sarcoma in preclinical models using a 64Cu-labeled anti-CD99 antibody.The decline and fall of the IGF-I receptor.Targeting IGF-1 signaling pathways in gynecologic malignancies.Optimal management of Ewing sarcoma family of tumors: recent developments in systemic therapy.Chemotherapy for osteosarcoma - where does it come from? What is it? Where is it going?Immunohistochemical analysis of insulin-like growth factor 1 and its receptor in sporadic schwannoma/peripheral nerve sheath tumour.Phosphorylated insulin-like growth factor-1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from lung adenocarcinomas.Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination StudiesNuclear translocation of IGF-1R via p150(Glued) and an importin-β/RanBP2-dependent pathway in cancer cells.Insulin-like growth factor axis targeting in cancer and tumour angiogenesis - the missing link.SUMO-modified insulin-like growth factor 1 receptor (IGF-1R) increases cell cycle progression and cell proliferation.IGF-1R expression is associated with HPV-negative status and adverse survival in head and neck squamous cell cancer.Nuclear insulin-like growth factor-1 receptor (IGF1R) displays proliferative and regulatory activities in non-malignant cells.Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma.Dynamics of IGF-1R expression during endocrine breast cancer treatment.
P2860
Q26742114-E5D902B8-50A3-4370-8FAE-BEFFDC351718Q26798408-14DB94C2-EBA4-483D-9E42-512DDDC1C645Q26826380-342AE115-26C5-42DB-AFF0-E9CD448372DCQ27612411-312E502A-D884-4023-8770-D917D8ECF989Q28082127-3731D7B0-1D6F-4ECD-92F2-7A4CFA59459AQ33276057-E6930639-BEEE-4DD2-862D-D9CE74DA584EQ33412198-D32AD072-4145-4CD5-AF3D-5CE9796F1CA4Q33658023-30119F2F-C309-4BE9-BB6F-0F99E0473002Q33752789-8194A0E1-A914-43E1-9A55-3AA4E28D8BC6Q34105623-6CEC83E0-0826-4593-806F-4D93812E807AQ34110523-16F6619F-1E03-4FBD-A990-21091E636613Q34336988-04A1461B-1BD9-4750-B632-75A47B0E515EQ34387886-430E2DF6-94DA-4110-B30F-9DC4C87D5773Q35061368-704FB831-6229-4A38-800F-8633D4EA284AQ35100621-6DB8EB79-FC33-4B9B-B744-243FCBCA5006Q35915343-E0557D8C-01C8-44C6-B66F-B727C7CF0BB0Q36907188-3CB0FC6A-44AB-449C-8D71-971D391EE691Q37486731-43DFB9F2-965E-455E-A3FA-6F1DCCF0DCF0Q37520529-D9159ED3-2C67-45C7-838F-1005C3E9C283Q37565198-23DC01F2-55B9-4F40-882C-EEA002858771Q37624249-CE49A916-7983-4BBF-87C2-8F6C41086275Q37624368-4FCFAA82-77B6-472E-89E6-0993F4C2079AQ38038480-09AA50C2-1E09-4F8D-93F4-153FB9326568Q38072115-B1354BF9-106E-4B7C-836F-E7B558EA5302Q38113988-5220D1C0-B96A-4BEA-9B13-AC086013AE61Q38126943-786CF68F-E842-4AC3-8839-478CF4FF16A3Q38380938-51D73D7D-F916-433F-8261-DF8422783475Q38395821-ECE55DE0-93F2-4560-8E68-A4E8E176C0C2Q38641329-29867D00-9BAA-4225-869F-7140D845EAE8Q38987162-1190204F-DDD4-4180-81A5-5E8C2D384A7BQ38990201-41693317-BD60-4D87-B9AD-31557145F16AQ41066789-2132CB62-EBA0-43CE-B792-6BA526C48946Q41303851-C24A0C53-42B9-4102-AD1F-A940BE1A60D6Q42363569-6D64D9C4-3F72-47B6-B0F0-478FABF8D272Q47148669-80902A29-BAF2-4CAA-A5CF-3547C1EB52C3Q51752849-E365FDBC-F18A-4373-8664-2D1D415BB39C
P2860
Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Insulin-like growth factor typ ...... body (Ab) therapy in sarcomas.
@ast
Insulin-like growth factor typ ...... body (Ab) therapy in sarcomas.
@en
Insulin-like growth factor typ ...... body (Ab) therapy in sarcomas.
@nl
type
label
Insulin-like growth factor typ ...... body (Ab) therapy in sarcomas.
@ast
Insulin-like growth factor typ ...... body (Ab) therapy in sarcomas.
@en
Insulin-like growth factor typ ...... body (Ab) therapy in sarcomas.
@nl
prefLabel
Insulin-like growth factor typ ...... body (Ab) therapy in sarcomas.
@ast
Insulin-like growth factor typ ...... body (Ab) therapy in sarcomas.
@en
Insulin-like growth factor typ ...... body (Ab) therapy in sarcomas.
@nl
P2093
P50
P921
P3181
P1476
Insulin-like growth factor typ ...... body (Ab) therapy in sarcomas.
@en
P2093
Adeline Duc
Dominique Ranchère
Emmanuel Watkin
Irène Asmane
Jean-Emmanuel Kurtz
Jean-Pierre Bergerat
Laurent Alberti
Perrine Marec-Berard
Philippe Cassier
P304
P3181
P356
10.1016/J.EJCA.2012.05.009
P577
2012-11-01T00:00:00Z